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Abstract
Several Locus-Specific DataBases (LSDBs) have recently been approached by larger, more 
general data repositories (including NCBI and UCSC) with the request to share the DNA variant 
data they have collected. Within the Human Genome Variation Society (HGVS) a document was 
generated summarizing the issues related to these requests. The document has been circulated in 
the HGVS/LSDB community and was discussed extensively. Here we summarize these 
discussions and present the concluded recommendations for LSDB data sharing with central 
repositories.
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Introduction
With full genome sequencing at hand, we need to develop much better tools to store and 
share existing and new data on sequence variation and its (potential) phenotypic 
consequences [Cotton et al., 2007a]. Thus, there is an increasing pressure to share the data 
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that curators of LSDBs have gathered [Cotton et al., 2008]. LSDB curators agree that data 
integration is more important than ever and information in LSDBs should be widely and 
easily available. Overall, they are supportive, but they also see data sharing potentially as a 
great risk and a threat. Their fear is that years of cautious quality-checked data collection 
and curation work will be given away for free, where it might be mixed with other lower 
quality data, and thus eventually lose much of its substance and raison d’être. Assuming 
appropriate conditions will be met to ensure adequate quality checks in these central 
repositories, additional concerns of LSDB curators need to be addressed, such as “What will 
be their recognition or their reward?” Currently, third parties sometimes take data without 
asking for permission, without giving proper acknowledgement or any reward, and 
sometimes the data are even used for profit. Furthermore, the LSDBs may envisage that the 
data will be shared once and then “repackaged” by a central repository. Who will need the 
LSDB after that? Who will warrant the data quality and provenance? Who owns the data?
For most, it is clear that there will be a role for everybody in this field. Currently, LSDBs 
provide the most accurate information resources with data quality and richness, especially 
regarding phenotype information, being much better than that available through other 
sources. Furthermore, compared to general data repositories, LSDBs mostly focus on a 
specific gene or condition and often develop specific additional tools.
A realistic threat exists that if LSDBs remain reluctant to share data, interested parties will 
find other ways to collect this information and bypass the LSDBs. In addition, LSDB 
curators often lack time and resources to devote to the maintenance and development of 
their database [Cotton et al., 2007b]. Consequently, they consider it the role of the data 
integrators to develop tools that accurately collect the information from LSDBs and make it 
more widely available. Overall, the central repositories have better resources and are much 
better qualified to perform this work (e.g., [Giardine et al., 2007]). The LSDB community 
can see the central collection, integration and redistribution of data as a positive issue; it will 
generate much more traffic and citations to their databases and thus provide more 
recognition. An intrinsic benefit for the LSDBs is that data quality and consistency will be 
checked when integrated with other resources. Also, redistribution ensures a more 
permanent record of the data. Finally, integration will facilitate collection and analysis of 
larger datasets, which adds reliability to the analysis of the effects of variants and to the 
evaluation of trends.
What Information Can We Expect to be Shared?
Minimal LSDB Information That Should Be Shared
1. Web address of the LSDB.
2. Contact details of the database curator(s).
3. Gene name, including the HGNC approved gene symbol, HGNC ID number, 
EntrezGene ID, MIM number (for genes and diseases).
4. DNA reference sequence used (GenBank or Ensembl accession + version number, 
preferably derived from the LRG-project as soon as these are available).
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5. Description of published sequence variants at the DNA level using HGVS 
recommendations (see below) and, when available, the description as in the original 
report, dbSNP ID, and/or MIM number of variant.
6. LSDB specific identifier(s) to link directly to the specific variant(s) in the LSDB.
Further LSDB Information That Could Be Shared
Besides the basic and minimal information mentioned above, LSDBs contain a wealth of 
additional information, especially regarding the phenotype of patients carrying specific 
variants. What additional information could an LSDB consider to share with a central 
repository?
1. Reference/PubMed ID: sharing the PubMed ID in relation to the variants is 
desirable but not without consequences. In many cases an LSDB description of the 
variant has been changed from that published to follow HGVS recommendations 
and/or errors have been corrected (often after contacting the authors). 
Consequently, those following the publication link through a central repository 
might be unable to view the change in that publication. Such confusion can be 
prevented when the PubMed link is obtained through the LSDB, assuming the 
LSDB mentions when and how changes were made in relation to the original 
publication. When a central repository clearly indicates that such discrepancies may 
exist, an LSDB could share this information.
2. Number of independent observations of a DNA variant: The question is, what 
number should be exchanged here? (1) the total number of individual patients 
identified—which tells something about frequency in the population, but some 
variants will be specific for certain ethnic groups only; or (2) the total number of 
unrelated families identified. LSDB opinions currently favor option (3) as a more 
useful number, even though in certain cases one knows that multiple reports of a 
variant, in fact, represent a single founder mutation. The most favored format to 
share this information is through choice from a set of categories, for example, 
found once, 2–10 times, 11–99 times, >100 times. This also reduces the effect of 
patients that, without the LSDB curator’s knowledge, have been reported several 
times in different publications.
3. Change at protein level: the change at protein level is in nearly 100% of cases a 
prediction based on the change found at DNA level. When desired, anybody can 
make this prediction. The consensus was that without experimental proof, an LSDB 
should not share this prediction. Experimental proof might exist when RNA or 
protein has been analyzed or when functional studies have been performed. If so, 
this information should be stored at the LSDBs (not usually done currently). 
LSDBs can share this information, but only when the central repository uses a 
discriminative display indicating the different levels of experimental proof.
4. Change at RNA level: at present, RNA is usually not analyzed, and any effect of a 
sequence variant at RNA level thus goes unnoticed. The increasing number of 
variants with unexpected consequences at the RNA level, mostly influencing 
splicing, that are reported underscores the danger of making a prediction based on 
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DNA sequence only. The considerations previously discussed under item 3 thus 
also apply to RNA. LSDBs should store this information when available and can 
then share it with a central repository.
5. Associated pathogenicity: although probably the most desired data field for 
sharing, this was generally considered the most problematic field. The definition of 
“pathogenic” itself varies depending on the specific clinical or biochemical criteria 
used [Easton et al., 2007; Plon et al., 2008]. For example, for the seemingly simple 
discrimination between Duchenne and Becker muscular dystrophies (DMD/BMD), 
submitters might use protein data, clinical data (e.g., the age ambulation is lost), or 
the genetic variant found. Opinions on disease symptoms may differ among clinical 
centres and countries, as does the naming of disease and symptoms. In rare 
diseases, small numbers make interpretation of variants rather risky. Large clinical 
heterogeneity (symptomatic and asymptomatic people) often can be observed even 
within a single family, attesting the influence of modifiers or incomplete 
penetrance. Furthermore, a given variant is generally tested on its own and only in 
relation to a specific disease; “no known pathogenicity” thus relates only to this 
specific phenotype and neglects any influence of the rest of the genome. In diseases 
such as Bardet-Biedl syndrome [Tayeh et al., 2008] or Retinitis Pigmentosa [Daiger 
et al., 2007], pathogenicity is dependent on the combined presence of variants in 
different genes that each alone may be nonpathogenic. Similarly, for multigenic 
diseases we can expect that frequent variants (single neucloetide polymorphisms 
[SNPs] or copy number variations [CNVs]), which most of the time behave as 
nonpathogenic, in certain cases change to pathogenic. To prevent easy 
misinterpretation, it will also be important to label pathogenic variants as either 
“dominant” or “recessive,” that is, sufficient on its own to cause disease or only in 
combination with a variant on the other allele. From an LSDB, this distinction 
should be obvious, from a central repository it might not. One option is to share 
data on pathogenicity for clear-cut cases only [Plon et al., 2008], that is, those 
variants that have been shown many times to be associated with pathogenicity and 
those that have no known association with disease. All others could be classified as 
“unknown.” Using more categories seems attractive, for example, “probably 
pathogenic” and “probably not pathogenic,” but their use on a central site is 
probably confusing for nonexperts. Furthermore, it would distract from the fact that 
to draw such a conclusion the source, that is, the LSDB, should be consulted. 
Another problem is inconsistency among reports. For example, within an LSDB 
one may find five reports listing a specific variant as “pathogenic,” three as 
“pathogenicity unknown” and another five as “no known pathogenicity.” What 
should be reported in such cases? Thus, when the criteria used to discriminate these 
categories are clearly stated, LSDBs can share pathogenicity information labelled 
as either “no known pathogenicity,” “unknown,” or “pathogenic.” The same holds 
true for a central repository, it should clearly state the criteria on which they made 
the distinction between the classes used. Preferably both parties use the same 
criteria, and it is advised to include strong disclaimers explaining the associated 
uncertainties.
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6. Unpublished/variants submitted directly to LSDB: before this information can 
be shared, LSDB curators should make it clear to their submitters that they might 
share the data collected, how they will do this, and specify what information will be 
shared. For existing unpublished records, LSDB curators would have to ask 
permission from the original submitter before data could be shared. LSDBs should 
have a public “database policy” paragraph explaining their principles in this 
respect. When LSDBs receive confidential variants (i.e., full records submitted but 
not yet released, e.g., while awaiting publication), these should not be shared. It has 
been suggested that LSDBs should follow a policy where data can be kept 
confidential for only a limited time, for example, 12 months, after which the data 
become public automatically.
What Needs to be Done?
Central Repositories
1. List collaborating curators and funders of the LSDB on the central site.
2. Make it clear from where the displayed DNA variant data have been obtained 
(LSDB address, logo) and explain how the data are displayed (i.e., the categories 
and criteria used, e.g., regarding consequences at protein level and in relation to 
pathogenicity).
3. Provide for every variant a direct link to that variant in the respective LSDB. Share 
the central repository ID files (e.g., assigned dbSNP numbers) to allow the LSDB 
to link to the central repository.
4. Decide on a policy to follow when there is more then one LSDB for a gene. Will 
links be provided to all LSDBs containing a specific variant or will one LSDB be 
selected? What will be done when LSDBs have conflicting data?
5. Upon request, assist LSDB curators with fundraising by writing letters of support 
stating that the requesting LSDB actively shares its data and the value this has had 
for the central repository. Similarly, where possible, the central repository will keep 
track of data usage and give LSDB curators access to these figures.
6. Establish standard systems and semantics for LSDB data sharing (including data 
format, sites for data uploads, etc.), enabling LSDB curators to easily share their 
data and software developers and integrators to build tools for regular automated 
data exchange.
7. Help LSDBs to obtain data they would like to receive, e.g. a list of all variants 
known to the central repository. Such a list can be very helpful for a curator to 
initiate a new gene variant database.
LSDBs
LSDBs will need to draft a “database policy” clearly explaining what they expect of the data 
submitted (e.g., that the submitter obtained informed consent) and what the LSDB may do 
with the data collected. This database policy should be clearly displayed at the LSDB Web 
site and should indicate whether data will be shared, which data, with whom, how, under 
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what conditions, and whether they will contact their submitters to discuss changes in LSDB 
policy. In addition, LSDBs should realize that when data are shared they immediately will 
have a new task, that is, regularly updating this shared information. LSDB software 
developers should note this demand and accordingly build in tools for data sharing.
Conclusion
Ideally, all sequence variant data, including variants causing disease, should be available on 
central browsers for safekeeping and integration with other data on the genome such as that 
generated by the ENCODE project [ENCODE Project Consortium 2007]. Such sharing has 
begun at UCSC [Giardine et al., 2007] (e.g., FKRP at http://globin.bx.psu.edu/phencode/
pui.html) and NCBI (Povey and Maglott, unpublished; e.g., TSC2 at http://
www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=7249). The concerns with data sharing are 
expressed in this paper, and a guide to the future is presented. Any comments should be 
expressed to the corresponding author or in a letter to the Editor.
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